Group 1: Policy Release - The report includes three domestic policies related to the bio-based industry [7][18]. - Key projects in the policies focus on carbon reduction and include initiatives for biodegradable polyester rubber, high-performance bio-based materials, and sustainable aviation fuel [8][19]. Group 2: Industry Dynamics - The report highlights two domestic developments in the bio-based chemicals sector, including a project for lactic acid production and the establishment of a new company for food additives [9][20]. - A total of 13 domestic developments in the bio-manufacturing sector are reported, including strategic collaborations and new project announcements [20][21]. Group 3: Capital Events - Several financing events in the bio-based sector are noted, with companies raising millions in funding for various bio-manufacturing projects [11][22]. - Notable investments include over 100 million yuan for recombinant collagen and nearly 100 million yuan for bioactive ingredients [22]. Group 4: Scientific Research Progress - Significant breakthroughs in scientific research related to bio-based materials and manufacturing are reported, including advancements in bioremediation and the synthesis of high-order carbohydrates [12][23]. - Research highlights include the development of engineered bacteria for pollutant degradation and innovative methods for synthesizing sugars from low-carbon molecules [23]. Group 5: Upcoming Events - The fourth Synthetic Biology and Green Bio-Manufacturing Conference is scheduled for August 20-22, 2025, in Jinan, Shandong, focusing on industry trends and technological innovations [25][26].

Core Viewpoint - The article emphasizes the transformative potential of synthetic biology in addressing sustainability challenges in traditional agricultural protein production, particularly through the development of microbial protein from non-grain raw materials [1][2]. Group 1: Technological Innovations - The research team has made significant breakthroughs in the use of methanol as a renewable C1 compound, enhancing the efficiency of converting methanol into single-cell protein through metabolic engineering and genomic perturbation [2]. - Innovations in gas-phase non-grain microbial protein production include the construction of a light-dark energy adapter in E. coli, enabling light-driven CO2 assimilation [2]. - The team has developed a machine learning model to decode the composition of degrading enzyme systems based on the structural characteristics of lignocellulose, facilitating the production of microbial protein from agricultural waste [2]. Group 2: Economic and Environmental Impact - The innovative conversion models not only enhance the economic value of agricultural waste but also pave the way for the industrial-scale biosynthesis of microbial protein from these resources, achieving a dual benefit of resource utilization [2]. - The research highlights the integration of synthetic biology and interdisciplinary innovation as a driving force for sustainable protein production, contributing to food security and carbon neutrality goals [6]. Group 3: Future Research Directions - Future research will focus on the super-evolutionary design of chassis cells, the closed-loop integration of negative carbon manufacturing systems, and the construction of AI-driven intelligent bio-manufacturing platforms [6].

团队前期的工作围绕甲醇作为一种可再生的 C1 化合物以及与二氧化碳氢化合成技术的重大突破，通过碳氮协同耦合代谢工程与基因组扰动等多重策 略，有效提升天然甲基营养菌中甲醇向单细胞蛋白的定向转化效率，进而突破工业菌株性能极限，为利用甲醇作为碳源生物制造微生物蛋白大规模工业 化生产提供了关键技术支持；在气态非粮生物制造微生物蛋白方面，通过构建大肠杆菌中的光 - 暗反应能量适配器，实现光驱动 CO 2 同化的全细胞 催化过程；通过电催化 - 生物耦合技术，可将电化学还原 CO 2 生成的甲酸盐与微生物同化模块精准对接，为气态非粮原料的转化技术开辟了负碳生 物制造微生物蛋白的新维度；在固态非粮原料生物合成微生物蛋白技术方面，该团队通过机器学习模型，基于木质纤维素结构特性破译出降解酶系组成 的新算法，进而摆脱复杂性底物结构 - 多样性酶系构效关系的实验先验，精准定制了多种地源性木质纤维素来源的微生物蛋白，达到地源性农业废弃 物资源利用与微生物蛋白生物合成"一草双收"效果。这些创新转化模式不仅提升了农业废弃物资源化利用经济价值，更开辟了农业废弃物规模化生物 合成微生物蛋白的工业化新路径。 以下文章来源于中国科学院天津工业生 ...

Project Overview - The project is named "Micro Yuan Synthesis Green Biological Manufacturing Phase II Health Sugar Project" with an investment of 40 million yuan [2] - The project aims to produce 2,000 tons annually of alitame and mannitol, utilizing existing fermentation and public utility equipment along with new membrane separation, ion exchange, concentration, crystallization, and drying equipment [2] - Alitame is a new low-calorie sweetener with various physiological benefits, while mannitol is widely used in pharmaceuticals, food, and chemicals as a sweetener, humectant, and excipient [2] Ongoing Projects - The "Micro Yuan Synthesis Green Biological Manufacturing Phase II Project" employs biological extraction technology to produce bilirubin from a fermentation process using glucose, citric acid, and other components, with an expected annual production of 5 tons of bilirubin upon completion [3] Company Background - Micro Yuan Synthesis Biotechnology (Qinhuangdao) Co., Ltd. is a wholly-owned subsidiary of Micro Yuan Synthesis Biotechnology (Beijing) Co., Ltd., established in May 2022 and located in the Qinhuangdao High-tech Industrial Development Zone [4] - The company focuses on innovation and industrialization in synthetic biology technology, providing bio-based raw materials and solutions for various industries including pharmaceuticals, daily chemicals, agriculture, food, feed, and materials [4]

Core Insights - The 10th Bio-based Conference and Exhibition was held in Shanghai from May 26-27, 2025, focusing on AI-enabled innovation in new materials and applications in bio-based materials [1][3][19] - The conference featured discussions on the development trends of the bio-manufacturing industry in China, highlighting its potential as a global bio-manufacturing center [3] - Various experts presented on the integration of AI in chemical new materials research and production, emphasizing the challenges and opportunities in this field [7][16] Group 1: Industry Trends and Insights - YiKai Capital's partner shared insights on the definition and market size of the global and Chinese bio-manufacturing industry, along with development trends and capital market reviews for 2024 and 2025 [3] - The Shanghai Academy of Science's researcher discussed a dual-driven molecular pre-training model that significantly improved reaction selectivity by five times and designed new biodegradable polymer materials [5] - The roundtable discussions included perspectives from investment institutions and scientific experts on how AI can enhance the efficiency of bio-based material research and development [9][15] Group 2: AI Applications in Material Science - The market director of Magnesium Technology presented on the application of AI in the research and production of chemical new materials, addressing the challenges faced in implementing these technologies [7] - A report on high-resolution atomic imaging analysis using deep learning highlighted the limitations of traditional models and introduced a new framework for analyzing structural diversity [11] - The application of AI in polymer material design was discussed, showcasing recent advancements and case studies in composite materials and organic photovoltaic materials [13]

中国发展网讯5月30日，由山东省科技厅指导，山东省创新发展研究院、山东大学、山东人才集团等共 同主办，山东科技大市场、山东大学微生物改造技术全国重点实验室、山东人才投资有限公司等联合承 办的"山东大学微生物改造技术全国重点实验室专场活动"在山东科技大市场成功举办。 山东省科技厅党组成员、山东省创新发展研究院党组书记、院长刘峰，山东大学科学技术研究院常务副 院长胡大伟，山东大学青岛校区副校长、山东大学微生物技术研究院院长李盛英出席活动并致辞。山东 国投公司党委副书记，山东人才集团党委副书记、董事、总经理杨光军，济南市科技局党组成员、副局 长吕家亮，山东产权交易集团党组委员、副总经理彭利民，山东省工业技术研究院副院长孟凯等领导出 席活动。 会上，山东大学的九项重大科技成果进行了发布路演，山东科技大市场及大市场线上平台、山东人才科 创投融资导航平台、山东省科融信平台运营单位负责人介绍了平台有关情况。会前，与会人员参观了山 东科技大市场展陈区、业态区。 本次活动邀请了省内各市科技局、高新区、农高区相关负责人和生物制造企业、生物医药企业技术成果 需求方和金融机构代表等130余人参会，旨在搭建校企、校地产学研合作交流的高 ...

Core Insights - The decline in valine prices in 2024 has led to a decrease in the company's profits [1] - The company is building an open R&D system and continuously upgrading its synthetic biology platform [1] Financial Performance - The company maintains a "buy" rating, adjusting the EPS for 2025-2027 to 1.12, 1.58, and 2.09 yuan respectively, down from previous estimates of 3.40 and 4.59 yuan [2] - In 2024, the company's net profit attributable to shareholders is expected to decrease by 57.80% [2] - The company's operating revenue for 2024 is projected to be 2.178 billion yuan, a year-on-year increase of 12.37% [2] - The net profit attributable to shareholders for 2024 is estimated at 190 million yuan, a decrease of 57.80% year-on-year [2] - The first quarter of 2025 is expected to show an operating revenue of 687 million yuan, a year-on-year increase of 37.20% [2] Product Development and R&D - The company is enhancing its product matrix by investing in new products such as 1,3-propanediol, succinic acid, tryptophan, and arginine [2] - The company plans to increase the implementation of the succinic acid project and adjust some capacity for L-valine and myo-inositol production [3] - The establishment of an AI digital laboratory aims to explore the application of AI technology in synthetic biology and company management [3] - The company is investing 320 million yuan to build an "AI Precision Fermentation and Protein Engineering Shared Demonstration Project" [3] - A "Biobased Polyester Textile Industry Alliance" has been established to accelerate domestic substitution of raw materials and promote innovation in the biobased polyester industry [3]

「璀璨女性」 为创业邦推出的系列栏目，致力于报道商界、投资界的女性力量，展现她们管理的智 慧，分享她们在困境中破局的勇气与力量。 作者丨卜松 编辑丨刘恒涛 图源 丨 元素驱动 元素驱动 （ 杭州）生物科技有限公司 （ 以下简称元素驱动 ）总部坐落在杭州西郊， 从大楼外观上看， 它 在园区 内 显得 并不特别 ，颇有"大隐隐于市"的味道。 然而，它 却是一家以前沿科技为驱动力，着眼打造人类未来生活图景的高科技企业。它以合成生物技 术，革新着传统化工产品的生产资源、生产方式，生产出新的产品或提高现有产品的生产效率——这就 是生物制造。 成立仅四年，元素驱动实现了绿色合成氨基酸、生物基高性能新材料的产品布局，从实验室走向了生产 线。刘旻昊是元素驱动的联合创始人、董事长，她正在带领团队，与传统企业携手，用生物制造方式来 解决行业绿色升级的难题。未来 ， 也许能见到他们用 生物合成氨基酸100%代替豆粕 养殖生猪 ； 也许还 能见到生物基材料被应用在与人类生活息息相关的各种领域。 元素驱动是西湖大学孵化的科技企业。 作为 全程参与西湖大学创办 的核心成员，刘旻昊曾 担任西湖大 学校长助理、西湖教育基金会秘书长、理事长。 ...

Core Viewpoint - Synthetic biology and biomanufacturing have gained significant attention and support from various sectors, including government, academia, and industry, highlighting their importance in driving innovation and economic growth in the biological economy [1][17]. Group 1: Event Overview - The SynBio China Third China Synthetic Biology "Scientists + Entrepreneurs + Investors" Expo will be held on August 1-2, 2025, at the Suzhou International Expo Center [3]. - The expo will feature seven sub-conferences, including discussions on synthetic biology applications in health, food, and cosmetics [3][11][15]. - The event aims to gather over 20,000 participants, showcasing the growing interest and investment in synthetic biology [3][33]. Group 2: Industry Challenges and Opportunities - Despite rapid concept dissemination, the synthetic biology industry in China faces challenges such as scaling production, realizing product value, and fostering market development [17]. - Synthetic biology is viewed as a key to understanding life and a disruptive technology that can significantly enhance China's biological economy [17]. - The industry is focused on promoting collaboration between research and enterprises to facilitate the translation of scientific achievements into practical applications [17][20]. Group 3: Technological Innovations - Advances in synthetic biology include the development of high-throughput reactors, enzyme catalysis, and microbial drug synthesis, which are crucial for biomanufacturing [8][12][15]. - Innovations in functional ingredients and personalized health foods driven by synthetic biology are expected to reshape the food industry [11][14]. - The application of synthetic biology in cosmetics and medical aesthetics is also being explored, with a focus on bio-synthesized ingredients [15][18].

Core Insights - The company, Huaheng Biological, announced an investment of 320 million yuan to establish an "Artificial Intelligence Precision Fermentation and Protein Engineering Shared Demonstration Project" in Changfeng County, Hefei [1] - This investment aims to enhance production efficiency and product quality through advanced microbial fermentation technology and AI-driven process control [1] - The project is expected to take 36 months to complete and will be funded primarily through the company's own or self-raised funds [1] Investment Details - The total investment agreements signed by the company with the Changfeng (Shuangfeng) Economic Development Zone Management Committee in the past 12 months amount to 710 million yuan, including a previous agreement of 390 million yuan for a "AI-driven Biological Manufacturing R&D and Pilot Demonstration Base" [2] - The new project will be located at the intersection of Shuangfeng Road and Yingzhou Road in the Shuangfeng Economic Development Zone [1] Technological Advancements - The investment will leverage cutting-edge technologies in synthetic biology and metabolic engineering, transitioning biological manufacturing from traditional fermentation to precision and intelligence [1] - The company aims to establish an intelligent production system to meet market demands for high-quality, low-cost products, thereby enhancing its core competitiveness and maintaining its industry leadership [1]